DBV Technologies (NASDAQ:DBVT) Shares Gap Down on Insider Selling

Shares of DBV Technologies S.A. (NASDAQ:DBVT) gapped down before the market opened on Monday following insider selling activity. The stock had previously closed at $22.76, but opened at $20.67. DBV Technologies shares last traded at $20.2670, with a volume of 124,159 shares traded.

Specifically, major shareholder Bpifrance Epic sold 1,292,103 shares of the company’s stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $4.19, for a total value of $5,413,911.57. Following the completion of the transaction, the insider directly owned 7,303,369 shares in the company, valued at approximately $30,601,116.11. This represents a 15.03% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Bpifrance Epic sold 2,076,990 shares of the business’s stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $4.85, for a total transaction of $10,073,401.50. Following the transaction, the insider owned 8,595,472 shares in the company, valued at $41,688,039.20. This represents a 19.46% decrease in their position. The SEC filing for this sale provides additional information.

Analyst Ratings Changes

Several analysts have weighed in on the company. Wall Street Zen raised DBV Technologies from a “sell” rating to a “hold” rating in a research report on Friday, November 28th. Guggenheim restated a “buy” rating and issued a $51.00 target price (up previously from $35.00) on shares of DBV Technologies in a research note on Wednesday, December 17th. Cantor Fitzgerald set a $48.00 price target on DBV Technologies in a research report on Wednesday, December 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of DBV Technologies in a report on Monday, December 8th. Finally, Citizens Jmp raised their price objective on DBV Technologies from $21.00 to $45.00 and gave the company a “market outperform” rating in a research report on Wednesday, December 17th. Two analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $35.38.

DBV Technologies Stock Performance

The stock has a 50-day moving average of $15.46 and a two-hundred day moving average of $11.96. The company has a market cap of $814.04 million, a P/E ratio of -3.92 and a beta of -1.10.

Hedge Funds Weigh In On DBV Technologies

Several institutional investors and hedge funds have recently modified their holdings of DBVT. New York State Common Retirement Fund purchased a new position in shares of DBV Technologies in the third quarter worth $34,000. Two Sigma Investments LP bought a new stake in DBV Technologies in the 3rd quarter worth about $167,000. Citadel Advisors LLC bought a new stake in DBV Technologies in the 3rd quarter worth about $220,000. DLD Asset Management LP purchased a new position in DBV Technologies in the 3rd quarter worth about $250,000. Finally, Nan Fung Trinity HK Ltd. bought a new position in DBV Technologies during the 2nd quarter valued at about $340,000. 71.74% of the stock is currently owned by institutional investors.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.